{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T15:03:29Z","timestamp":1791299009957,"version":"4.1.0"},"reference-count":39,"publisher":"American Medical Association (AMA)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"<jats:sec><jats:title>Importance<\/jats:title><jats:p>Rapidly acting therapeutics like 3,4-methylenedioxymethamphetamine (MDMA) are promising treatments for disorders such as posttraumatic stress disorder (PTSD). However, understanding who benefits most and the underlying neural mechanisms remains a critical gap. Stratifying individuals by neural circuit profiles could help differentiate neural, behavioral, and affective responses to MDMA, enabling personalized treatment strategies.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>To investigate whether baseline stratification of individuals based on negative affect circuit profiles, particularly in response to nonconscious threat stimuli, can differentiate acute responses to MDMA.<\/jats:p><\/jats:sec><jats:sec><jats:title>Design, Setting, and Participants<\/jats:title><jats:p>This randomized clinical trial, implementing a double-blinded, within-participant, placebo- and baseline-controlled design, was conducted at Stanford University School of Medicine between November 2, 2021, and November 9, 2022, for wave 1 data collection. Participants had used MDMA on at least 2 prior occasions, but not in the past 6 months, and had subthreshold PTSD symptoms and early life trauma but no current psychiatric disorders. Data were analyzed from March 1, 2023, to January 1, 2024.<\/jats:p><\/jats:sec><jats:sec><jats:title>Interventions<\/jats:title><jats:p>Participants completed 4 visits: 1 baseline session followed by 1 placebo session and 2 MDMA sessions in a randomized order, totaling 64 visits. Baseline functional magnetic resonance imaging (fMRI) assessed the negative affect circuit using a nonconscious threat processing task (NTN).<\/jats:p><\/jats:sec><jats:sec><jats:title>Main Outcomes and Measures<\/jats:title><jats:p>Primary outcomes included activity and connectivity of amygdala and subgenual anterior cingulate cortex (sgACC) defining the negative affect circuit. Secondary outcomes were behavioral measures of implicit threat bias, likability of threat expressions, and affective assessments.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Sixteen participants (10 [63%] female; mean [SD] age, 40.8 [7.6] years) were stratified into subgroups with high and low levels of NTN activity in the amygdala (NTN<jats:sub>A+<\/jats:sub> [n\u2009=\u20098] and NTN<jats:sub>A\u2212<\/jats:sub> [n\u2009=\u20098], respectively), based on a median split of baseline nonconscious threat-evoked fMRI responses. Following administration of the 120 mg of MDMA vs placebo, the NTN<jats:sub>A+<\/jats:sub> subgroup showed significant reductions in amygdala (contrast estimate [CE], \u22121.43; 95% CI, \u22122.60 to \u22120.27; Cohen <jats:italic>d<\/jats:italic>, \u22121.22; <jats:italic>P<\/jats:italic>\u2009=\u2009.02) and sgACC activity (CE, \u22121.48; 95% CI, \u22122.42 to \u22120.54; Cohen <jats:italic>d<\/jats:italic>, \u22121.56; <jats:italic>P<\/jats:italic>\u2009=\u2009.004), increased sgACC-amygdala connectivity (CE, 0.65; 95% CI, 0.02-1.28; Cohen <jats:italic>d<\/jats:italic>, 1.02; <jats:italic>P<\/jats:italic>\u2009=\u2009.04), and increased likability of threat expressions (CE, 14.38; 95% CI, 1.46-27.29; Cohen <jats:italic>d<\/jats:italic>, 0.86; <jats:italic>P<\/jats:italic>\u2009=\u2009.03) compared with the NTN<jats:sub>A\u2212<\/jats:sub> subgroup.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions and Relevance<\/jats:title><jats:p>In this randomized clinical trial of MDMA\u2019s acute profiles, 120 mg of MDMA acutely normalized negative affect circuit reactivity in participants stratified by heightened amygdala reactivity at baseline, demonstrating the potential of neuroimaging to identify prospective biomarkers and guide personalized MDMA-based therapies.<\/jats:p><\/jats:sec><jats:sec><jats:title>Trial Registration<\/jats:title><jats:p>ClinicalTrials.gov Identifier: <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/study\/NCT04060108\">NCT04060108<\/jats:ext-link><\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2025.7803","type":"journal-article","created":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T23:30:25Z","timestamp":1746055825000},"page":"e257803","source":"Crossref","is-referenced-by-count":13,"title":["Negative Affect Circuit Subtypes and Neural, Behavioral, and Affective Responses to MDMA"],"prefix":"10.1001","volume":"8","author":[{"given":"Xue","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura M.","family":"Hack","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, California"},{"name":"Sierra-Pacific Mental Illness Research, Education and Clinical Center, Veterans Affairs Palo Alto Health Care System, Palo Alto, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Bertrand","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Hilton","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy J.","family":"Gray","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leyla","family":"Boyar","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Laudie","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris D.","family":"Heifets","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, California"},{"name":"Department of Anesthesiology, Perioperative and Pain Medicine, Stanford University School of Medicine, Stanford, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trisha","family":"Suppes","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, California"},{"name":"Veterans Affairs Palo Alto Health Care System, Palo Alto, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J.","family":"van Roessel","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, California"},{"name":"Sierra-Pacific Mental Illness Research, Education and Clinical Center, Veterans Affairs Palo Alto Health Care System, Palo Alto, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn I.","family":"Rodriguez","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, California"},{"name":"Veterans Affairs Palo Alto Health Care System, Palo Alto, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl","family":"Deisseroth","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, California"},{"name":"Department of Bioengineering, Stanford University, Stanford, California"},{"name":"Howard Hughes Medical Institute, Stanford University, Stanford, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Knutson","sequence":"additional","affiliation":[{"name":"Department of Psychology, Stanford University, Stanford, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leanne M.","family":"Williams","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, California"},{"name":"Sierra-Pacific Mental Illness Research, Education and Clinical Center, Veterans Affairs Palo Alto Health Care System, Palo Alto, California"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2025,4,30]]},"reference":[{"issue":"15","key":"zoi250287r1","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1001\/jama.2017.3826","article-title":"Depression is the leading cause of disability around the world.","volume":"317","author":"Friedrich","year":"2017","journal-title":"JAMA"},{"key":"zoi250287r2","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.jpsychires.2021.01.039","article-title":"Functional impairment in posttraumatic stress disorder: a systematic review and meta-analysis.","volume":"136","author":"Jellestad","year":"2021","journal-title":"J Psychiatr Res"},{"issue":"7","key":"zoi250287r3","doi-asserted-by":"publisher","first-page":"2964","DOI":"10.1038\/s41380-023-01995-3","article-title":"Distinctively different human neurobiological responses after trauma exposure and implications for posttraumatic stress disorder subtyping.","volume":"28","author":"Lee","year":"2023","journal-title":"Mol Psychiatry"},{"issue":"2","key":"zoi250287r4","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1001\/jamapsychiatry.2022.4092","article-title":"The heterogeneity of posttraumatic stress disorder in DSM-5.","volume":"80","author":"Bryant","year":"2023","journal-title":"JAMA Psychiatry"},{"issue":"1","key":"zoi250287r5","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s12916-017-0849-x","article-title":"The new field of \u201cprecision psychiatry\u201d.","volume":"15","author":"Fernandes","year":"2017","journal-title":"BMC Med"},{"issue":"1","key":"zoi250287r7","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/s41398-024-02781-7","article-title":"Elevating the field for applying neuroimaging to individual patients in psychiatry.","volume":"14","author":"Roalf","year":"2024","journal-title":"Transl Psychiatry"},{"issue":"3","key":"zoi250287r8","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1176\/appi.ajp.2019.19010060","article-title":"Individual patterns of abnormality in resting-state functional connectivity reveal two data-driven PTSD subgroups.","volume":"177","author":"Maron-Katz","year":"2020","journal-title":"Am J Psychiatry"},{"issue":"568","key":"zoi250287r9","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaz9343","article-title":"Evaluating the evidence for a neuroimaging subtype of posttraumatic stress disorder.","volume":"12","author":"Esterman","year":"2020","journal-title":"Sci Transl Med"},{"issue":"9","key":"zoi250287r10","doi-asserted-by":"publisher","DOI":"10.1176\/appi.pn.2022.09.9.23","article-title":"Special report: precision psychiatry\u2014are we getting closer?","volume":"57","author":"Williams","year":"2022","journal-title":"Psychiatric News"},{"issue":"486","key":"zoi250287r11","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aal3236","article-title":"Using fMRI connectivity to define a treatment-resistant form of post-traumatic stress disorder.","volume":"11","author":"Etkin","year":"2019","journal-title":"Sci Transl Med"},{"issue":"9","key":"zoi250287r12","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/S0006-3223(00)00828-3","article-title":"Exaggerated amygdala response to masked facial stimuli in posttraumatic stress disorder: a functional MRI study.","volume":"47","author":"Rauch","year":"2000","journal-title":"Biol Psychiatry"},{"issue":"5","key":"zoi250287r13","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1002\/hbm.20415","article-title":"Enhanced amygdala and medial prefrontal activation during nonconscious processing of fear in posttraumatic stress disorder: an fMRI study.","volume":"29","author":"Bryant","year":"2008","journal-title":"Hum Brain Mapp"},{"issue":"2","key":"zoi250287r14","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1002\/da.22156","article-title":"Cortico-limbic responses to masked affective faces across PTSD, panic disorder, and specific phobia.","volume":"31","author":"Killgore","year":"2014","journal-title":"Depress Anxiety"},{"issue":"6","key":"zoi250287r15","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.biopsych.2021.06.024","article-title":"Mapping neural circuit biotypes to symptoms and behavioral dimensions of depression and anxiety.","volume":"91","author":"Goldstein-Piekarski","year":"2022","journal-title":"Biol Psychiatry"},{"issue":"36","key":"zoi250287r16","doi-asserted-by":"publisher","first-page":"9264","DOI":"10.1523\/JNEUROSCI.1016-06.2006","article-title":"Mode of functional connectivity in amygdala pathways dissociates level of awareness for signals of fear.","volume":"26","author":"Williams","year":"2006","journal-title":"J Neurosci"},{"issue":"7","key":"zoi250287r17","doi-asserted-by":"publisher","first-page":"2076","DOI":"10.1038\/s41591-024-03057-9","article-title":"Personalized brain circuit scores identify clinically distinct biotypes in depression and anxiety.","volume":"30","author":"Tozzi","year":"2024","journal-title":"Nat Med"},{"issue":"2","key":"zoi250287r18","doi-asserted-by":"publisher","first-page":"141","DOI":"10.31887\/DCNS.2015.17.2\/jflory","article-title":"Comorbidity between post-traumatic stress disorder and major depressive disorder: alternative explanations and treatment considerations.","volume":"17","author":"Flory","year":"2015","journal-title":"Dialogues Clin Neurosci"},{"issue":"10","key":"zoi250287r19","doi-asserted-by":"publisher","first-page":"2398","DOI":"10.1038\/npp.2015.89","article-title":"Amygdala reactivity to emotional faces in the prediction of general and medication-specific responses to antidepressant treatment in the randomized iSPOT-D trial.","volume":"40","author":"Williams","year":"2015","journal-title":"Neuropsychopharmacology"},{"issue":"4","key":"zoi250287r20","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1017\/S0033291707002231","article-title":"Amygdala and ventral anterior cingulate activation predicts treatment response to cognitive behaviour therapy for post-traumatic stress disorder.","volume":"38","author":"Bryant","year":"2008","journal-title":"Psychol Med"},{"issue":"21","key":"zoi250287r21","doi-asserted-by":"publisher","first-page":"4219","DOI":"10.1007\/s00213-014-3570-x","article-title":"MDMA alters emotional processing and facilitates positive social interaction.","volume":"231","author":"Wardle","year":"2014","journal-title":"Psychopharmacology (Berl)"},{"issue":"6","key":"zoi250287r22","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1038\/s41591-021-01336-3","article-title":"MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study.","volume":"27","author":"Mitchell","year":"2021","journal-title":"Nat Med"},{"issue":"10","key":"zoi250287r23","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1038\/s41591-023-02565-4","article-title":"MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial.","volume":"29","author":"Mitchell","year":"2023","journal-title":"Nat Med"},{"key":"zoi250287r25","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2022.947622","article-title":"Altered brain activity and functional connectivity after MDMA-assisted therapy for post-traumatic stress disorder.","volume":"13","author":"Singleton","year":"2023","journal-title":"Front Psychiatry"},{"issue":"1","key":"zoi250287r26","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s00213-009-1635-z","article-title":"Effects of MDMA on sociability and neural response to social threat and social reward.","volume":"207","author":"Bedi","year":"2009","journal-title":"Psychopharmacology (Berl)"},{"issue":"8","key":"zoi250287r28","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1002\/da.20854","article-title":"Negative biases and risk for depression: integrating self-report and emotion task markers.","volume":"28","author":"Watters","year":"2011","journal-title":"Depress Anxiety"},{"issue":"3","key":"zoi250287r29","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1080\/13803390802255635","article-title":"Explicit identification and implicit recognition of facial emotions, I: age effects in males and females across 10 decades.","volume":"31","author":"Williams","year":"2009","journal-title":"J Clin Exp Neuropsychol"},{"issue":"1","key":"zoi250287r32","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.neuroimage.2004.08.016","article-title":"A direct brainstem-amygdala-cortical \u201calarm\u201d system for subliminal signals of fear.","volume":"24","author":"Liddell","year":"2005","journal-title":"Neuroimage"},{"issue":"2","key":"zoi250287r33","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.tics.2010.11.004","article-title":"Emotional processing in anterior cingulate and medial prefrontal cortex.","volume":"15","author":"Etkin","year":"2011","journal-title":"Trends Cogn Sci"},{"issue":"9","key":"zoi250287r34","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/S0006-3223(01)01263-X","article-title":"Increased amygdala response to masked emotional faces in depressed subjects resolves with antidepressant treatment: an fMRI study.","volume":"50","author":"Sheline","year":"2001","journal-title":"Biol Psychiatry"},{"key":"zoi250287r35","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1016\/j.nicl.2016.10.007","article-title":"Neural changes in extinction recall following prolonged exposure treatment for PTSD: a longitudinal fMRI study.","volume":"12","author":"Helpman","year":"2016","journal-title":"Neuroimage Clin"},{"issue":"2","key":"zoi250287r36","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s10879-017-9379-2","article-title":"Current perspective on MDMA-assisted psychotherapy for posttraumatic stress disorder.","volume":"48","author":"Thal","year":"2018","journal-title":"J Contemp Psychother"},{"issue":"10","key":"zoi250287r37","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1038\/s44220-024-00324-z","article-title":"Why reliving is not remembering and the unique neurobiological representation of traumatic memory.","volume":"2","author":"Kearney","year":"2024","journal-title":"Nat Ment Health"},{"issue":"5","key":"zoi250287r38","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1177\/0269881121998322","article-title":"Prediction of MDMA response in healthy humans: a pooled analysis of placebo-controlled studies.","volume":"35","author":"Studerus","year":"2021","journal-title":"J Psychopharmacol"},{"key":"zoi250287r39","doi-asserted-by":"publisher","DOI":"10.1038\/d41586-024-02597-x","article-title":"FDA rejects ecstasy as a therapy: what\u2019s next for psychedelics?","author":"Reardon","year":"2024","journal-title":"Nature"},{"key":"zoi250287r6","volume-title":"Neuroimaging for Precision Medicine in Psychiatry","author":"Williams","year":"2024"},{"key":"zoi250287r24","author":"Multidisciplinary Association for Psychedelic Studies","year":"2017"},{"key":"zoi250287r27","doi-asserted-by":"crossref","unstructured":"Williams? LM. A platform for standardized, online delivered, clinically applicable neurocognitive assessment: Webneuro.? bioRxiv. Preprint posted online September 28, 2024. doi:10.1101\/2023.08.28.553107","DOI":"10.1101\/2023.08.28.553107"},{"key":"zoi250287r30","unstructured":"Pinheiro J, Bates D, DebRoy S, et al. nlme: Linear and Nonlinear Mixed Effects Models. Accessed March 1, 2023. https:\/\/CRAN.R-project.org\/package=nlme"},{"key":"zoi250287r31","unstructured":"Ben-Shachar MS, Makowski D, L\u00fcdecke D, et al. effectsize: Indices of effect size. Accessed March 1, 2023. https:\/\/cran.r-project.org\/web\/packages\/effectsize\/index.html"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2833328\/zhang_2025_oi_250287_1745261961.81633.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T23:30:27Z","timestamp":1746055827000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2833328"}},"subtitle":["A Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2025,4,30]]},"references-count":39,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.7803","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,30]]}}}